News
PNT
12.50
0.00%
0.00
Weekly Report: what happened at PNT last week (0226-0301)?
Weekly Report · 03/04 10:07
Weekly Report: what happened at PNT last week (0219-0223)?
Weekly Report · 02/26 10:13
Radiopharmaceutical market expected to reach ~$14B by 2032
The international market for radiopharmaceuticals is expected to reach $13.67B by 2032. Radiopharma market expected to grow at a compound annual growth rate of 10.2% from 2023. The rising prevalence of cancer and an aging population are among the tailwinds for market growth.
Seeking Alpha · 02/25 17:00
Weekly Report: what happened at PNT last week (0212-0216)?
Weekly Report · 02/19 10:15
Weekly Report: what happened at PNT last week (0205-0209)?
Weekly Report · 02/12 10:09
Weekly Report: what happened at PNT last week (0129-0202)?
Weekly Report · 02/05 10:13
Weekly Report: what happened at PNT last week (0122-0126)?
Weekly Report · 01/29 10:08
Weekly Report: what happened at PNT last week (0115-0119)?
Weekly Report · 01/22 10:10
Weekly Report: what happened at PNT last week (0108-0112)?
Weekly Report · 01/15 10:08
Weekly Report: what happened at PNT last week (0101-0105)?
Weekly Report · 01/08 10:10
The retail sector has a major conference next week - watch these stocks
Consumer The retail sector has a major conference next week. The ICR Conference runs in Orlando, Florida from January 8-10. The update from Lululemon may be of the closest watched of the bunch. Nike's earnings report in December set a gloomy tone for the retail sector.
Seeking Alpha · 01/06 14:26
Catalyst Watch: CES lights up tech, retail's ICR conference and bank earnings blitz
Seeking Alpha's Catalyst Watch looks at next week's key events. The J.P. Morgan Healthcare Conference is one of the biggest tech conferences of the year. The Manheim Car Price Index report will be released on January 8. The retail's ICR conference and bank earnings blitz are scheduled for January 9.
Seeking Alpha · 01/05 19:30
Weekly Report: what happened at PNT last week (1225-1229)?
Weekly Report · 01/01 10:07
Point Biopharma Global Inc: [Amend]General statement of acquisition of beneficial ownership
Press release · 12/28/2023 04:03
Point Biopharma Global Inc: Statement of changes in beneficial ownership of securities
Press release · 12/28/2023 04:03
More
Webull provides a variety of real-time PNT stock news. You can receive the latest news about Point Biopharma Global Inc through multiple platforms. This information may help you make smarter investment decisions.
About PNT
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.